Immunogenicity and Safety of Different Combinations Involving a Third Booster Dose of SARS-CoV-2 Inactivated Vaccine, Inactivated Quadrivalent Influenza Vaccine, and 23-Valent Pneumococcal Polysaccharide Vaccine in Adults Aged ≥60 Years: a Phase 4, Randomized, Open-Label Study